Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

References

• Herikstad H, Yang S, Van Gilder TJ et al. A population-based estimate of the burden of diarrheal illness in the United States: FoodNet, 1996–1997. Epidemiol. Infect. 129, 9–17 (2002).
   PubMed Web of Science ®Google Scholar
• Mead PS, Slutsker L, Dietz V et al. Food-related illness and death in the United States. Emerg. Infect. Dis. 5, 607–625 (1999).
   PubMed Web of Science ®Google Scholar
• Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49, 467–484 (1995).
   PubMed Web of Science ®Google Scholar
• Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a nonabsorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomized trial. Curr. Med. Res. Opin. 13, 593–601 (1997).
   PubMed Web of Science ®Google Scholar
• Corazza GR, Ventrucci M, Strocchi A et al. Treatment of small intestine bacterial overgrowth with rifaximin, a nonabsorbable rifamycin. J. Int. Med. Res. 16, 312–316 (1988).
   PubMed Web of Science ®Google Scholar
• Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers’ diarrhea. J. Travel Med. 8, S34–S39 (2001).
   Google Scholar
• Gomi H, Jiang ZD, Adachi JA et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing travelers’ diarrhea in four geographic regions. Antimicrob. Agents Chemother. 45, 212–216 (2001).
   PubMed Web of Science ®Google Scholar
• Sierra JM, Navia MM, Vargas M et al. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhea in children under 5 years of age in Ifakara, Tanzania. J. Antimicrob. Chemother. 47, 904–905 (2001).
   PubMed Web of Science ®Google Scholar
• Sierra JM, Ruiz J, Navia MM, Vargas M, Vila J. In vitro activity of rifaximin against enteropathogens producing travelers’ diarrhea. Antimicrob. Agents Chemother. 45, 643–644 (2001).
   PubMed Web of Science ®Google Scholar
• Scrascia M, Forcillo M, Maimone F, Pazzani C. Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas. J. Antimicrob. Chemother. 52, 303–305 (2003).
   PubMedGoogle Scholar
• Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn. Microbiol. Infect. Dis. 16, 111–118 (1993).
   PubMed Web of Science ®Google Scholar
• Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J. Antimicrob. Chemother. 35, 545–549 (1995).
   PubMed Web of Science ®Google Scholar
• Megraud F, Bouffant F, Camou Juncas C. In vitro activity of rifaximin against Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 13, 184–186 (1994).
   PubMedGoogle Scholar
• Ripa S, Mignini F, Prenna M, Falcioni E. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp. Clin. Res. 13, 483–488 (1987).
   PubMedGoogle Scholar
• Farr BM. Rifamycins. In: Principles and Practice of Infectious Disease. Mandell GS, Bennett JE, Dolin R (Eds). Churchill Livingston, PA, USA, 348–360 (2000).
   Google Scholar
• Testa R, Eftimiadi C, Sukkar GS et al. A nonabsorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp. Clin. Res. 11, 387–392 (1985).
   PubMedGoogle Scholar
• DuPont HL, Jiang Z-D. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin. Micro. Infect. Dis. 10, 1006–1035 (2004).
   Google Scholar
• Venturini AP, Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 5, 257–262 (1986).
   PubMedGoogle Scholar
• Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int. J. Clin. Pharmacol. Res. 14, 51–56 (1994).
   PubMedGoogle Scholar
• Rizzello F, Gionchetti P, Venturi A et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 54, 91–93 (1998).
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother. 44, 2205–2206 (2000).
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 66, 246–256 (2002).
   PubMed Web of Science ®Google Scholar
• Helwig U, Gionchetti P, Rizzello F et al. CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. Int. J. Colorectal. Dis. 19, 165–170 (2004).
   PubMed Web of Science ®Google Scholar
• Crump JA, Sulka AC, Langer AJ et al. An outbreak of Escherichia coli O157:H7 infections among visitors to a dairy farm. N. Engl. J. Med. 347, 555–560 (2002).
   PubMed Web of Science ®Google Scholar
• Sherlock O, Schembri MA, Reisner A, Klemm P. Novel roles for the AIDA adhesin from diarrheagenic Escherichia coli: cell aggregation and biofilm formation. J. Bacteriol. 186, 8058–8065 (2004).
   PubMed Web of Science ®Google Scholar
• Huang DB, Okhuysen PC, Jiang ZD, DuPont HL. Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am. J. Gastroenterol. 99, 383–389 (2004).
   PubMed Web of Science ®Google Scholar
• Peck KR, Kim SW, Jung SI et al. Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis. Chemotherapy 49, 189–193 (2003).
   PubMed Web of Science ®Google Scholar
• Zheng Z, Stewart PS. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob. Agents Chemother. 46, 900–903 (2002).
   PubMed Web of Science ®Google Scholar
• Jones SM, Morgan M, Humphrey TJ, Lappin-Scott H. Effect of vancomycin and rifampicin on methicillin-resistant Staphylococcus aureus biofilms. Lancet 357, 40–41 (2001).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Ericsson CD et al. Rifaximin versus ciprofloxacin for the treatment of travelers’ diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis. 33, 1807–1815 (2001).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Mathewson JJ et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion 59, 708–714 (1998).
   PubMed Web of Science ®Google Scholar
• Steffen R, Sack DA, Riopel L et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am. J. Gastroenterol. 98, 1073–1078 (2003).
   PubMed Web of Science ®Google Scholar
• Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr. Med. Res. Opin. 13, 109–118 (1993).
   PubMed Web of Science ®Google Scholar
• Mas A, Rodes J, Sunyer L et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J. Hepatol. 38, 51–58 (2003).
   PubMed Web of Science ®Google Scholar
• Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr. Med. Res. Opin. 13, 274–281 (1995).
   PubMed Web of Science ®Google Scholar
• Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital. J. Gastroenterol. 23, 175–178 (1991).
   PubMedGoogle Scholar
• Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Ail. Pharmaco. Ther. 14, 551–556 (2000).
   PubMed Web of Science ®Google Scholar
• Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr. Med. Res. Opin. 15, 47–52 (1999).
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory-bowel disease. N. Engl. J. Med. 347, 417–429 (2002).
   PubMed Web of Science ®Google Scholar
• Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory-bowel disease. Clin. Microbiol. Rev. 15, 79–94 (2002).
   PubMed Web of Science ®Google Scholar
• Shanahan F. Crohn’s disease. Lancet 359, 62–69 (2002).
   PubMed Web of Science ®Google Scholar
• Scribano ML, Prantera C. Review article: medical treatment of active Crohn’s disease. Ail. Pharmaco. Ther. 16(Suppl. 4), 35–39 (2002).
   PubMedGoogle Scholar
• Shafran I, Johnson LK, Hamm L, Murdock RH. Efficacy and tolerability of rifaximin, a nonabsorbed oral antibiotic, in the treatment of active Crohn’s disease, results of an open-label study. Presented at the 68th Annual American College of Gastroenterology Meeting. Orlando, FL, USA, 10–15 October 2003.
   Google Scholar
• Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig. Dis. Sci. 44, 1220–1221 (1999).
   PubMed Web of Science ®Google Scholar
• Pinto A, Borruto G, Dell’Anna A, Turco L, Ferrieri A. An open, uncontrolled trial of oral rifaximin, a nonabsorbable antibiotic, in inflammatory-bowel disease refractory to conventional therapy. Eur. J. Clin. Res. 9, 217–224 (1997).
   Google Scholar
• Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 124, 1636–1650 (2003).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Ail. Pharmaco. Ther. 13, 713–718 (1999).
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch. Intern. Med. 161, 525–533 (2001).
   PubMed Web of Science ®Google Scholar
• Boero M, Berti E, Morgando A, Verme G. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiol. Medica 5, 74–77 (1990).
   Google Scholar
• Infante RM, Ericsson CD, Jiang ZD et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin. Gastroenterol. Hepatol. 2, 135–138 (2004).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang Z-D, Okhuysen PC et al. Randomized placebo-controlled trial of rifaximin prevention of travelers’ diarrhea in Mexico where diarrheagenic E. coli are major causes of illness. Ann. Intern. Med. (In Press).
   Google Scholar
• Taylor DN, McKenzie R, Durbin A et al. Double-blind, placebo-controlled trial to evaluate the use of rifaximin (200 mg t.i.d.) to prevent diarrhea in subjects challenged with Shigella flexneri 2a (2457t). 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene. Miami, FL, USA, 7–11 November 2004 (Abstract).
   Google Scholar
• Rifaximin (Xifaxan) for travelers’ diarrhea. Med. Lett. Drugs Ther. 46, 74–75 (2004).
   PubMedGoogle Scholar